Phyrago

Overview

dasatinib

kinase inhibitor

• CYP3A4 substrate
• antiplatelet effects
• gastric pH sensitive
• hyperuricemic effects
• immunosuppressive oncologic agent
• myelosuppressive oncologic agent
• prolongs QT interval (conditional)

Contraindicated

• chikungunya vaccine, live
Phyrago (dasatinib)

+

chikungunya vaccine, live

3 interactions

Contraindicated

dasatinib + chikungunya vaccine, live

contraindicated; vaccinate at least 4wk before or 3mo after dasatinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• varicella vaccine, live
Phyrago (dasatinib)

+

varicella vaccine, live

1 interaction

Contraindicated

dasatinib + varicella vaccine, live

contraindicated; vaccinate at least 4wk before or 3mo after dasatinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• yellow fever vaccine, live
Phyrago (dasatinib)

+

yellow fever vaccine, live

1 interaction

Contraindicated

dasatinib + yellow fever vaccine, live

contraindicated; vaccinate at least 4wk before or 3mo after dasatinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

Avoid/Use Alternative

• adagrasib
Phyrago (dasatinib)

+

adagrasib

2 interactions

Avoid/Use Alternative

dasatinib + adagrasib

use alternative or monitor ECG, electrolytes, CBC; consider decr. dasatinib dose as follows: if taking dasatinib 140 mg/day, decr. dose to 40 mg/day; if taking dasatinib 70-100 mg/day, decr. dose to 20 mg/day; if taking dasatinib 40-60 mg/day, consider holding dasatinib during and x1wk after adagrasib tx: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• ceritinib
Phyrago (dasatinib)

+

ceritinib

3 interactions

Avoid/Use Alternative

dasatinib + ceritinib

use alternative or monitor ECG, electrolytes, CBC; consider decr. dasatinib dose as follows: if taking dasatinib 140 mg/day, decr. dose to 40 mg/day; if taking dasatinib 70-100 mg/day, decr. dose to 20 mg/day; if taking dasatinib 40-60 mg/day, consider holding dasatinib during and x1wk after ceritinib tx: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• cimetidine
Phyrago (dasatinib)

+

cimetidine

2 interactions

Avoid/Use Alternative

dasatinib + cimetidine

use alternative, incl. short-acting antacids 2h before or 2h after dasatinib; Phyrago use ok: combo may decr. dasatinib levels, efficacy (absorption decreased at higher gastric pH)

• cisapride
Phyrago (dasatinib)

+

cisapride

2 interactions

Avoid/Use Alternative

dasatinib + cisapride

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• cladribine oral
Phyrago (dasatinib)

+

cladribine oral

2 interactions

Avoid/Use Alternative

dasatinib + cladribine oral

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• clarithromycin
Phyrago (dasatinib)

+

clarithromycin

2 interactions

Avoid/Use Alternative

dasatinib + clarithromycin

use alternative or monitor ECG, electrolytes, CBC; consider decr. dasatinib dose as follows: if taking dasatinib 140 mg/day, decr. dose to 40 mg/day; if taking dasatinib 70-100 mg/day, decr. dose to 20 mg/day; if taking dasatinib 40-60 mg/day, consider holding dasatinib during and x1wk after clarithromycin tx: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• cobicistat
Phyrago (dasatinib)

+

cobicistat

2 interactions

Avoid/Use Alternative

dasatinib + cobicistat

use alternative or monitor ECG, CBC; consider decr. dasatinib dose as follows: if taking dasatinib 140 mg/day, decr. dose to 40 mg/day; if taking dasatinib 70-100 mg/day, decr. dose to 20 mg/day; if taking dasatinib 40-60 mg/day, consider holding dasatinib during and x1wk after cobicistat tx: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• crizotinib
Phyrago (dasatinib)

+

crizotinib

3 interactions

Avoid/Use Alternative

dasatinib + crizotinib

use alternative or monitor ECG, electrolytes, CBC: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• deferiprone
Phyrago (dasatinib)

+

deferiprone

2 interactions

Avoid/Use Alternative

dasatinib + deferiprone

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• dexlansoprazole
Phyrago (dasatinib)

+

dexlansoprazole

2 interactions

Avoid/Use Alternative

dasatinib + dexlansoprazole

use alternative, incl. short-acting antacids 2h before or 2h after dasatinib; Phyrago use ok: combo may decr. dasatinib levels, efficacy (absorption decreased at higher gastric pH)

• dexrazoxane
Phyrago (dasatinib)

+

dexrazoxane

2 interactions

Avoid/Use Alternative

dasatinib + dexrazoxane

monitor CBC if anthracycline extravasation or doxorubicin cardioprotective use, otherwise avoid combo: combo may incr. risk of myelosuppression; may decr. efficacy of cancer chemo (additive effects; mechanism unknown)

• domperidone
Phyrago (dasatinib)

+

domperidone

1 interaction

Avoid/Use Alternative

dasatinib + domperidone

use alternative or monitor ECG, HR, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dronedarone
Phyrago (dasatinib)

+

dronedarone

1 interaction

Avoid/Use Alternative

dasatinib + dronedarone

use alternative or monitor ECG, electrolytes, CBC: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• encorafenib
Phyrago (dasatinib)

+

encorafenib

1 interaction

Avoid/Use Alternative

dasatinib + encorafenib

use alternative or consider incr. dasatinib dose; monitor ECG, electrolytes, bleeding s/sx: combo may incr. risk of QT prolongation, cardiac arrhythmias, GI or other bleeding, incl. life-threatening; may decr. dasatinib levels, efficacy (additive effects; hepatic metab. induced)

• enoxaparin
Phyrago (dasatinib)

+

enoxaparin

1 interaction

Avoid/Use Alternative

dasatinib + enoxaparin

use alternative or monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• enzalutamide
Phyrago (dasatinib)

+

enzalutamide

1 interaction

Avoid/Use Alternative

dasatinib + enzalutamide

use alternative or consider incr. dasatinib dose: combo may decr. dasatinib levels, efficacy (hepatic metab. induced)

• ephedra
Phyrago (dasatinib)

+

ephedra

1 interaction

Avoid/Use Alternative

dasatinib + ephedra

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• esomeprazole
Phyrago (dasatinib)

+

esomeprazole

1 interaction

Avoid/Use Alternative

dasatinib + esomeprazole

use alternative, incl. short-acting antacids 2h before or 2h after dasatinib; Phyrago use ok: combo may decr. dasatinib levels, efficacy (absorption decreased at higher gastric pH)

• famotidine
Phyrago (dasatinib)

+

famotidine

1 interaction

Avoid/Use Alternative

dasatinib + famotidine

use alternative, incl. short-acting antacids 2h before or 2h after dasatinib; Phyrago use ok: combo may decr. dasatinib levels, efficacy (absorption decreased at higher gastric pH)

• fexinidazole
Phyrago (dasatinib)

+

fexinidazole

2 interactions

Avoid/Use Alternative

dasatinib + fexinidazole

if possible, do not initiate fexinidazole until 5 half-lives after dasatinib D/C; use alternative or monitor CBC, ECG, electrolytes, during and x7 days after fexinidazole tx: combo may decr. dasatinib levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (hepatic metab. induced; additive effects)

• fondaparinux
Phyrago (dasatinib)

+

fondaparinux

1 interaction

Avoid/Use Alternative

dasatinib + fondaparinux

use alternative or monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• fosphenytoin
Phyrago (dasatinib)

+

fosphenytoin

1 interaction

Avoid/Use Alternative

dasatinib + fosphenytoin

use alternative or consider incr. dasatinib dose: combo may decr. dasatinib levels, efficacy (hepatic metab. induced)

• ganciclovir
Phyrago (dasatinib)

+

ganciclovir

2 interactions

Avoid/Use Alternative

dasatinib + ganciclovir

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• grapefruit
Phyrago (dasatinib)

+

grapefruit

2 interactions

Avoid/Use Alternative

dasatinib + grapefruit

avoid grapefruit juice: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (GI metab. inhibited)

• hydroxychloroquine
Phyrago (dasatinib)

+

hydroxychloroquine

2 interactions

Avoid/Use Alternative

dasatinib + hydroxychloroquine

use alternative or monitor ECG, electrolytes, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• idelalisib
Phyrago (dasatinib)

+

idelalisib

3 interactions

Avoid/Use Alternative

dasatinib + idelalisib

use alternative or monitor ECG, CBC; consider decr. dasatinib dose as follows: if taking dasatinib 140 mg/day, decr. dose to 40 mg/day; if taking dasatinib 70-100 mg/day, decr. dose to 20 mg/day; if taking dasatinib 40-60 mg/day, consider holding dasatinib during and x1wk after idelalisib tx: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• nelfinavir
Phyrago (dasatinib)

+

nelfinavir

3 interactions

Avoid/Use Alternative

dasatinib + nelfinavir

use alternative or monitor ECG, CBC; consider decr. dasatinib dose as follows: if taking dasatinib 140 mg/day, decr. dose to 40 mg/day; if taking dasatinib 70-100 mg/day, decr. dose to 20 mg/day; if taking dasatinib 40-60 mg/day, consider holding dasatinib during and x1wk after nelfinavir tx: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• nizatidine
Phyrago (dasatinib)

+

nizatidine

2 interactions

Avoid/Use Alternative

dasatinib + nizatidine

use alternative, incl. short-acting antacids 2h before or 2h after dasatinib; Phyrago use ok: combo may decr. dasatinib levels, efficacy (absorption decreased at higher gastric pH)

• omeprazole
Phyrago (dasatinib)

+

omeprazole

2 interactions

Avoid/Use Alternative

dasatinib + omeprazole

use alternative, incl. short-acting antacids 2h before or 2h after dasatinib; Phyrago use ok: combo may decr. dasatinib levels, efficacy (absorption decreased at higher gastric pH)

• pacritinib
Phyrago (dasatinib)

+

pacritinib

2 interactions

Avoid/Use Alternative

dasatinib + pacritinib

avoid combo: combo may decr. dasatinib levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias, GI or other bleeding, incl. life-threatening (hepatic metab. induced, additive effects)

• palifermin
Phyrago (dasatinib)

+

palifermin

1 interaction

Avoid/Use Alternative

dasatinib + palifermin

avoid palifermin admin. w/in 24h before, during tx, or w/in 24h after myelotoxic chemo; otherwise, caution advised: combo may incr. severity and duration of oral mucositis (antagonistic effects)

• pantoprazole
Phyrago (dasatinib)

+

pantoprazole

1 interaction

Avoid/Use Alternative

dasatinib + pantoprazole

use alternative, incl. short-acting antacids 2h before or 2h after dasatinib; Phyrago use ok: combo may decr. dasatinib levels, efficacy (absorption decreased at higher gastric pH)

• penicillamine
Phyrago (dasatinib)

+

penicillamine

1 interaction

Avoid/Use Alternative

dasatinib + penicillamine

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• primaquine
Phyrago (dasatinib)

+

primaquine

1 interaction

Avoid/Use Alternative

dasatinib + primaquine

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• primidone
Phyrago (dasatinib)

+

primidone

1 interaction

Avoid/Use Alternative

dasatinib + primidone

use alternative or consider incr. dasatinib dose: combo may decr. dasatinib levels, efficacy (hepatic metab. induced)

• rifabutin
Phyrago (dasatinib)

+

rifabutin

1 interaction

Avoid/Use Alternative

dasatinib + rifabutin

use alternative or monitor CBC; consider incr. dasatinib dose: combo may decr. dasatinib levels, efficacy; may incr. risk of myelosuppression (hepatic metab. induced; additive effects)

• rifampin
Phyrago (dasatinib)

+

rifampin

1 interaction

Avoid/Use Alternative

dasatinib + rifampin

use alternative or consider incr. dasatinib dose: combo may decr. dasatinib levels, efficacy (hepatic metab. induced)

• ritonavir
Phyrago (dasatinib)

+

ritonavir

2 interactions

Avoid/Use Alternative

dasatinib + ritonavir

use alternative or monitor ECG, CBC; consider decr. dasatinib dose as follows: if taking dasatinib 140 mg/day, decr. dose to 40 mg/day; if taking dasatinib 70-100 mg/day, decr. dose to 20 mg/day; if taking dasatinib 40-60 mg/day, consider holding dasatinib during and x1wk after ritonavir tx: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• ropeginterferon alfa-2b
Phyrago (dasatinib)

+

ropeginterferon alfa-2b

1 interaction

Avoid/Use Alternative

dasatinib + ropeginterferon alfa-2b

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• sotalol
Phyrago (dasatinib)

+

sotalol

1 interaction

Avoid/Use Alternative

dasatinib + sotalol

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• St. John's wort
Phyrago (dasatinib)

+

St. John's wort

1 interaction

Avoid/Use Alternative

dasatinib + St. John's wort

avoid combo: combo may decr. dasatinib levels, efficacy (hepatic metab. induced)

• tipranavir
Phyrago (dasatinib)

+

tipranavir

1 interaction

Avoid/Use Alternative

dasatinib + tipranavir

use alternative or monitor ECG, CBC, bleeding s/sx; consider decr. dasatinib dose as follows: if taking dasatinib 140 mg/day, decr. dose to 40 mg/day; if taking dasatinib 70-100 mg/day, decr. dose to 20 mg/day; if taking dasatinib 40-60 mg/day, consider holding dasatinib during and x1wk after tipranavir tx: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, GI or other bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited, additive effects)

• toremifene
Phyrago (dasatinib)

+

toremifene

1 interaction

Avoid/Use Alternative

dasatinib + toremifene

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• tucatinib
Phyrago (dasatinib)

+

tucatinib

1 interaction

Avoid/Use Alternative

dasatinib + tucatinib

use alternative or monitor ECG, CBC; consider decr. dasatinib dose as follows: if taking dasatinib 140 mg/day, decr. dose to 40 mg/day; if taking dasatinib 70-100 mg/day, decr. dose to 20 mg/day; if taking dasatinib 40-60 mg/day, consider holding dasatinib during and x1wk after tucatinib tx: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• valganciclovir
Phyrago (dasatinib)

+

valganciclovir

1 interaction

Avoid/Use Alternative

dasatinib + valganciclovir

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• vandetanib
Phyrago (dasatinib)

+

vandetanib

1 interaction

Avoid/Use Alternative

dasatinib + vandetanib

use alternative or monitor ECG, electrolytes, bleeding s/sx: combo may incr. risk of QT prolongation, cardiac arrhythmias, GI or other bleeding, incl. life-threatening (additive effects)

• vonoprazan
Phyrago (dasatinib)

+

vonoprazan

1 interaction

Avoid/Use Alternative

dasatinib + vonoprazan

use alternative, incl. short-acting antacids 2h before or 2h after dasatinib; Phyrago use ok: combo may decr. dasatinib levels, efficacy (absorption decreased at higher gastric pH)

• voriconazole
Phyrago (dasatinib)

+

voriconazole

1 interaction

Avoid/Use Alternative

dasatinib + voriconazole

use alternative or monitor ECG, CBC; consider decr. dasatinib dose as follows: if taking dasatinib 140 mg/day, decr. dose to 40 mg/day; if taking dasatinib 70-100 mg/day, decr. dose to 20 mg/day; if taking dasatinib 40-60 mg/day, consider holding dasatinib during and x1wk after voriconazole tx: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• ziprasidone
Phyrago (dasatinib)

+

ziprasidone

1 interaction

Avoid/Use Alternative

dasatinib + ziprasidone

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

Monitor/Modify Tx

• abrocitinib
Phyrago (dasatinib)

+

abrocitinib

1 interaction

Monitor/Modify Tx

dasatinib + abrocitinib

monitor platelets, bleeding s/sx, especially during abrocitinib tx initiation or if abrocitinib 200 mg/day: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• acalabrutinib
Phyrago (dasatinib)

+

acalabrutinib

1 interaction

Monitor/Modify Tx

dasatinib + acalabrutinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• ado-trastuzumab emtansine
Phyrago (dasatinib)

+

ado-trastuzumab emtansine

1 interaction

Monitor/Modify Tx

dasatinib + ado-trastuzumab emtansine

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• afatinib
Phyrago (dasatinib)

+

afatinib

1 interaction

Monitor/Modify Tx

dasatinib + afatinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• albendazole
Phyrago (dasatinib)

+

albendazole

1 interaction

Monitor/Modify Tx

dasatinib + albendazole

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• alemtuzumab
Phyrago (dasatinib)

+

alemtuzumab

1 interaction

Monitor/Modify Tx

dasatinib + alemtuzumab

monitor CBC; myelosuppression risk may be lower w/ alemtuzumab doses used for MS: combo may incr. risk of myelosuppression (additive effects)

• allopurinol
Phyrago (dasatinib)

+

allopurinol

1 interaction

Monitor/Modify Tx

dasatinib + allopurinol

monitor CBC, uric acid levels: combo may incr. risk of myelosuppression; may decr. allopurinol efficacy (additive effects; antagonistic effects)

• alteplase
Phyrago (dasatinib)

+

alteplase

1 interaction

Monitor/Modify Tx

dasatinib + alteplase

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• aluminum hydroxide
Phyrago (dasatinib)

+

aluminum hydroxide

1 interaction

Monitor/Modify Tx

dasatinib + aluminum hydroxide

give dasatinib at least 2h before or 2h after aluminum hydroxide: combo may decr. dasatinib levels, efficacy (absorption decreased at higher gastric pH)

• amiodarone
Phyrago (dasatinib)

+

amiodarone

1 interaction

Monitor/Modify Tx

dasatinib + amiodarone

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• anacaulase topical
Phyrago (dasatinib)

+

anacaulase topical

1 interaction

Monitor/Modify Tx

dasatinib + anacaulase topical

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• anagrelide
Phyrago (dasatinib)

+

anagrelide

1 interaction

Monitor/Modify Tx

dasatinib + anagrelide

monitor ECG, electrolytes, bleeding s/sx: combo may incr. risk of QT prolongation, cardiac arrhythmias, GI or other bleeding, incl. life-threatening (additive effects)

• anthrax vaccine
Phyrago (dasatinib)

+

anthrax vaccine

1 interaction

Monitor/Modify Tx

dasatinib + anthrax vaccine

if possible, vaccinate at least 2wk before starting dasatinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• anti-thymocyte globulin
Phyrago (dasatinib)

+

anti-thymocyte globulin

1 interaction

Monitor/Modify Tx

dasatinib + anti-thymocyte globulin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• antithrombin
Phyrago (dasatinib)

+

antithrombin

1 interaction

Monitor/Modify Tx

dasatinib + antithrombin

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• apixaban
Phyrago (dasatinib)

+

apixaban

1 interaction

Monitor/Modify Tx

dasatinib + apixaban

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• apomorphine
Phyrago (dasatinib)

+

apomorphine

1 interaction

Monitor/Modify Tx

dasatinib + apomorphine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• aprepitant
Phyrago (dasatinib)

+

aprepitant

1 interaction

Monitor/Modify Tx

dasatinib + aprepitant

if aprepitant 3-day regimen, monitor ECG, CBC; aprepitant single dose-regimen OK: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• artemether/lumefantrine
Phyrago (dasatinib)

+

artemether/ lumefantrine

1 interaction

Monitor/Modify Tx

dasatinib + artemether/ lumefantrine

monitor ECG, electrolytes: combo may decr. dasatinib levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metab. induced; additive effects)

• asenapine
Phyrago (dasatinib)

+

asenapine

1 interaction

Monitor/Modify Tx

dasatinib + asenapine

monitor ECG, electrolytes, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• asparaginase
Phyrago (dasatinib)

+

asparaginase

1 interaction

Monitor/Modify Tx

dasatinib + asparaginase

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• aspirin
Phyrago (dasatinib)

+

aspirin

1 interaction

Monitor/Modify Tx

dasatinib + aspirin

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• atidarsagene autotemcel
Phyrago (dasatinib)

+

atidarsagene autotemcel

1 interaction

Monitor/Modify Tx

dasatinib + atidarsagene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

• auranofin
Phyrago (dasatinib)

+

auranofin

1 interaction

Monitor/Modify Tx

dasatinib + auranofin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• avacopan
Phyrago (dasatinib)

+

avacopan

1 interaction

Monitor/Modify Tx

dasatinib + avacopan

monitor ECG, CBC: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• avapritinib
Phyrago (dasatinib)

+

avapritinib

1 interaction

Monitor/Modify Tx

dasatinib + avapritinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• axitinib
Phyrago (dasatinib)

+

axitinib

1 interaction

Monitor/Modify Tx

dasatinib + axitinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• azathioprine
Phyrago (dasatinib)

+

azathioprine

1 interaction

Monitor/Modify Tx

dasatinib + azathioprine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• azithromycin
Phyrago (dasatinib)

+

azithromycin

1 interaction

Monitor/Modify Tx

dasatinib + azithromycin

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• balsalazide
Phyrago (dasatinib)

+

balsalazide

1 interaction

Monitor/Modify Tx

dasatinib + balsalazide

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• baricitinib
Phyrago (dasatinib)

+

baricitinib

1 interaction

Monitor/Modify Tx

dasatinib + baricitinib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• benznidazole
Phyrago (dasatinib)

+

benznidazole

1 interaction

Monitor/Modify Tx

dasatinib + benznidazole

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• berotralstat
Phyrago (dasatinib)

+

berotralstat

1 interaction

Monitor/Modify Tx

dasatinib + berotralstat

monitor ECG, CBC: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• betibeglogene autotemcel
Phyrago (dasatinib)

+

betibeglogene autotemcel

1 interaction

Monitor/Modify Tx

dasatinib + betibeglogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

• bevacizumab
Phyrago (dasatinib)

+

bevacizumab

1 interaction

Monitor/Modify Tx

dasatinib + bevacizumab

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• binimetinib
Phyrago (dasatinib)

+

binimetinib

1 interaction

Monitor/Modify Tx

dasatinib + binimetinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• bivalirudin
Phyrago (dasatinib)

+

bivalirudin

1 interaction

Monitor/Modify Tx

dasatinib + bivalirudin

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• brentuximab vedotin
Phyrago (dasatinib)

+

brentuximab vedotin

1 interaction

Monitor/Modify Tx

dasatinib + brentuximab vedotin

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• bromelain
Phyrago (dasatinib)

+

bromelain

1 interaction

Monitor/Modify Tx

dasatinib + bromelain

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• bromfenac ophthalmic
Phyrago (dasatinib)

+

bromfenac ophthalmic

1 interaction

Monitor/Modify Tx

dasatinib + bromfenac ophthalmic

monitor bleeding s/sx: combo may incr. risk of postop ocular bleeding (additive effects)

• cabazitaxel
Phyrago (dasatinib)

+

cabazitaxel

1 interaction

Monitor/Modify Tx

dasatinib + cabazitaxel

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• cabozantinib
Phyrago (dasatinib)

+

cabozantinib

1 interaction

Monitor/Modify Tx

dasatinib + cabozantinib

monitor ECG, electrolytes, bleeding s/sx: combo may incr. risk of QT prolongation, cardiac arrhythmias, GI or other bleeding, incl. life-threatening (additive effects)

• calaspargase
Phyrago (dasatinib)

+

calaspargase

1 interaction

Monitor/Modify Tx

dasatinib + calaspargase

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• calcium carbonate
Phyrago (dasatinib)

+

calcium carbonate

1 interaction

Monitor/Modify Tx

dasatinib + calcium carbonate

give dasatinib at least 2h before or 2h after calcium carbonate: combo may decr. dasatinib levels, efficacy (absorption decreased at higher gastric pH)

• cangrelor
Phyrago (dasatinib)

+

cangrelor

1 interaction

Monitor/Modify Tx

dasatinib + cangrelor

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• caplacizumab
Phyrago (dasatinib)

+

caplacizumab

1 interaction

Monitor/Modify Tx

dasatinib + caplacizumab

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• carfilzomib
Phyrago (dasatinib)

+

carfilzomib

1 interaction

Monitor/Modify Tx

dasatinib + carfilzomib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• celecoxib
Phyrago (dasatinib)

+

celecoxib

1 interaction

Monitor/Modify Tx

dasatinib + celecoxib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• chikungunya vaccine
Phyrago (dasatinib)

+

chikungunya vaccine

1 interaction

Monitor/Modify Tx

dasatinib + chikungunya vaccine

if possible, vaccinate at least 2wk before starting dasatinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• chloroquine
Phyrago (dasatinib)

+

chloroquine

1 interaction

Monitor/Modify Tx

dasatinib + chloroquine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• cidofovir
Phyrago (dasatinib)

+

cidofovir

1 interaction

Monitor/Modify Tx

dasatinib + cidofovir

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• cilostazol
Phyrago (dasatinib)

+

cilostazol

1 interaction

Monitor/Modify Tx

dasatinib + cilostazol

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• ciprofloxacin
Phyrago (dasatinib)

+

ciprofloxacin

1 interaction

Monitor/Modify Tx

dasatinib + ciprofloxacin

monitor ECG, CBC: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• citalopram
Phyrago (dasatinib)

+

citalopram

1 interaction

Monitor/Modify Tx

dasatinib + citalopram

monitor ECG, electrolytes, bleeding s/sx: combo may incr. risk of QT prolongation, cardiac arrhythmias, GI or other bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• clofazimine
Phyrago (dasatinib)

+

clofazimine

1 interaction

Monitor/Modify Tx

dasatinib + clofazimine

monitor ECG, electrolytes, CBC: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• clopidogrel
Phyrago (dasatinib)

+

clopidogrel

1 interaction

Monitor/Modify Tx

dasatinib + clopidogrel

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• clozapine
Phyrago (dasatinib)

+

clozapine

1 interaction

Monitor/Modify Tx

dasatinib + clozapine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• colchicine
Phyrago (dasatinib)

+

colchicine

1 interaction

Monitor/Modify Tx

dasatinib + colchicine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• collagenase clostridium histolyticum
Phyrago (dasatinib)

+

collagenase clostridium histolyticum

1 interaction

Monitor/Modify Tx

dasatinib + collagenase clostridium histolyticum

monitor injection site bleeding s/sx: combo may incr. risk of localized bleeding, incl. severe (additive effects)

• conivaptan
Phyrago (dasatinib)

+

conivaptan

1 interaction

Monitor/Modify Tx

dasatinib + conivaptan

monitor ECG, CBC during and x7 days after conivaptan tx: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• COVID-19 vaccine
Phyrago (dasatinib)

+

COVID-19 vaccine

1 interaction

Monitor/Modify Tx

dasatinib + COVID-19 vaccine

if possible, vaccinate at least 2wk before starting dasatinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cyclophosphamide
Phyrago (dasatinib)

+

cyclophosphamide

1 interaction

Monitor/Modify Tx

dasatinib + cyclophosphamide

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• cyclosporine
Phyrago (dasatinib)

+

cyclosporine

1 interaction

Monitor/Modify Tx

dasatinib + cyclosporine

monitor ECG, CBC: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• cysteamine
Phyrago (dasatinib)

+

cysteamine

1 interaction

Monitor/Modify Tx

dasatinib + cysteamine

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• dabigatran
Phyrago (dasatinib)

+

dabigatran

1 interaction

Monitor/Modify Tx

dasatinib + dabigatran

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• dalteparin
Phyrago (dasatinib)

+

dalteparin

1 interaction

Monitor/Modify Tx

dasatinib + dalteparin

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• danazol
Phyrago (dasatinib)

+

danazol

1 interaction

Monitor/Modify Tx

dasatinib + danazol

monitor ECG, CBC: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• danshen
Phyrago (dasatinib)

+

danshen

1 interaction

Monitor/Modify Tx

dasatinib + danshen

monitor bleeding s/sx: combo may decr. dasatinib levels, efficacy; may incr. risk of GI or other bleeding, incl. life-threatening (hepatic metab. induced; additive effects)

• dapsone
Phyrago (dasatinib)

+

dapsone

1 interaction

Monitor/Modify Tx

dasatinib + dapsone

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• darunavir
Phyrago (dasatinib)

+

darunavir

1 interaction

Monitor/Modify Tx

dasatinib + darunavir

monitor ECG, CBC: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• deferasirox
Phyrago (dasatinib)

+

deferasirox

1 interaction

Monitor/Modify Tx

dasatinib + deferasirox

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, GI or other bleeding, incl. life-threatening (additive effects)

• defibrotide
Phyrago (dasatinib)

+

defibrotide

1 interaction

Monitor/Modify Tx

dasatinib + defibrotide

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• degarelix
Phyrago (dasatinib)

+

degarelix

1 interaction

Monitor/Modify Tx

dasatinib + degarelix

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• desflurane
Phyrago (dasatinib)

+

desflurane

1 interaction

Monitor/Modify Tx

dasatinib + desflurane

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• desipramine
Phyrago (dasatinib)

+

desipramine

1 interaction

Monitor/Modify Tx

dasatinib + desipramine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• desvenlafaxine
Phyrago (dasatinib)

+

desvenlafaxine

1 interaction

Monitor/Modify Tx

dasatinib + desvenlafaxine

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• deuruxolitinib
Phyrago (dasatinib)

+

deuruxolitinib

1 interaction

Monitor/Modify Tx

dasatinib + deuruxolitinib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, GI or other bleeding, incl. life-threatening (additive effects)

• dexmedetomidine
Phyrago (dasatinib)

+

dexmedetomidine

1 interaction

Monitor/Modify Tx

dasatinib + dexmedetomidine

monitor HR, ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dexmedetomidine injection
Phyrago (dasatinib)

+

dexmedetomidine injection

1 interaction

Monitor/Modify Tx

dasatinib + dexmedetomidine injection

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• diclofenac
Phyrago (dasatinib)

+

diclofenac

1 interaction

Monitor/Modify Tx

dasatinib + diclofenac

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• diclofenac ophthalmic
Phyrago (dasatinib)

+

diclofenac ophthalmic

1 interaction

Monitor/Modify Tx

dasatinib + diclofenac ophthalmic

monitor bleeding s/sx: combo may incr. risk of postop ocular bleeding (additive effects)

• diclofenac topical
Phyrago (dasatinib)

+

diclofenac topical

1 interaction

Monitor/Modify Tx

dasatinib + diclofenac topical

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• diflunisal
Phyrago (dasatinib)

+

diflunisal

1 interaction

Monitor/Modify Tx

dasatinib + diflunisal

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• diltiazem
Phyrago (dasatinib)

+

diltiazem

1 interaction

Monitor/Modify Tx

dasatinib + diltiazem

monitor ECG, CBC: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• dimethyl fumarate
Phyrago (dasatinib)

+

dimethyl fumarate

1 interaction

Monitor/Modify Tx

dasatinib + dimethyl fumarate

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• diosmin
Phyrago (dasatinib)

+

diosmin

1 interaction

Monitor/Modify Tx

dasatinib + diosmin

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• diphtheria/tetanus vaccine
Phyrago (dasatinib)

+

diphtheria/ tetanus vaccine

1 interaction

Monitor/Modify Tx

dasatinib + diphtheria/ tetanus vaccine

if possible, vaccinate at least 2wk before starting dasatinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• diphtheria/tetanus/pertussis vaccine
Phyrago (dasatinib)

+

diphtheria/ tetanus/ pertussis vaccine

1 interaction

Monitor/Modify Tx

dasatinib + diphtheria/ tetanus/ pertussis vaccine

if possible, vaccinate at least 2wk before starting dasatinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• dipyridamole
Phyrago (dasatinib)

+

dipyridamole

1 interaction

Monitor/Modify Tx

dasatinib + dipyridamole

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• diroximel fumarate
Phyrago (dasatinib)

+

diroximel fumarate

1 interaction

Monitor/Modify Tx

dasatinib + diroximel fumarate

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• disopyramide
Phyrago (dasatinib)

+

disopyramide

1 interaction

Monitor/Modify Tx

dasatinib + disopyramide

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dofetilide
Phyrago (dasatinib)

+

dofetilide

1 interaction

Monitor/Modify Tx

dasatinib + dofetilide

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• donepezil
Phyrago (dasatinib)

+

donepezil

1 interaction

Monitor/Modify Tx

dasatinib + donepezil

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dordaviprone
Phyrago (dasatinib)

+

dordaviprone

1 interaction

Monitor/Modify Tx

dasatinib + dordaviprone

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• droperidol
Phyrago (dasatinib)

+

droperidol

1 interaction

Monitor/Modify Tx

dasatinib + droperidol

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• duloxetine
Phyrago (dasatinib)

+

duloxetine

1 interaction

Monitor/Modify Tx

dasatinib + duloxetine

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• duvelisib
Phyrago (dasatinib)

+

duvelisib

1 interaction

Monitor/Modify Tx

dasatinib + duvelisib

monitor ECG, CBC: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• ebola vaccine, live
Phyrago (dasatinib)

+

ebola vaccine, live

1 interaction

Monitor/Modify Tx

dasatinib + ebola vaccine, live

consider vaccinating at least 4wk before or 3mo after dasatinib tx: combo may result in inadequate vaccine response; may incr. risk of mild vesicular stomatitis virus infection (immunosuppressive effects, recombinant vaccine w/ vesicular stomatitis virus vector)

• edoxaban
Phyrago (dasatinib)

+

edoxaban

1 interaction

Monitor/Modify Tx

dasatinib + edoxaban

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• efbemalenograstim alfa
Phyrago (dasatinib)

+

efbemalenograstim alfa

1 interaction

Monitor/Modify Tx

dasatinib + efbemalenograstim alfa

admin. efbemalenograstim at least 24h after or at least 14 days before myelosuppressive chemo: combo may decr. efbemalenograstim efficacy (antagonistic effects)

• eflapegrastim (G-CSF)
Phyrago (dasatinib)

+

eflapegrastim (G-CSF)

1 interaction

Monitor/Modify Tx

dasatinib + eflapegrastim (G-CSF)

admin. eflapegrastim >24h after or >14 days before myelosuppressive chemo: combo may decr. eflapegrastim efficacy (antagonistic effects)

• elivaldogene autotemcel
Phyrago (dasatinib)

+

elivaldogene autotemcel

1 interaction

Monitor/Modify Tx

dasatinib + elivaldogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

• epirubicin
Phyrago (dasatinib)

+

epirubicin

1 interaction

Monitor/Modify Tx

dasatinib + epirubicin

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• epoprostenol
Phyrago (dasatinib)

+

epoprostenol

1 interaction

Monitor/Modify Tx

dasatinib + epoprostenol

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• eptifibatide
Phyrago (dasatinib)

+

eptifibatide

1 interaction

Monitor/Modify Tx

dasatinib + eptifibatide

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• eribulin
Phyrago (dasatinib)

+

eribulin

1 interaction

Monitor/Modify Tx

dasatinib + eribulin

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• erlotinib
Phyrago (dasatinib)

+

erlotinib

1 interaction

Monitor/Modify Tx

dasatinib + erlotinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• erythromycin
Phyrago (dasatinib)

+

erythromycin

1 interaction

Monitor/Modify Tx

dasatinib + erythromycin

monitor ECG, electrolytes, CBC: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• escitalopram
Phyrago (dasatinib)

+

escitalopram

1 interaction

Monitor/Modify Tx

dasatinib + escitalopram

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• ethanol
Phyrago (dasatinib)

+

ethanol

1 interaction

Monitor/Modify Tx

dasatinib + ethanol

monitor bleeding s/sx w/ orally ingested alcohol: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• etodolac
Phyrago (dasatinib)

+

etodolac

1 interaction

Monitor/Modify Tx

dasatinib + etodolac

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• evening primrose oil
Phyrago (dasatinib)

+

evening primrose oil

1 interaction

Monitor/Modify Tx

dasatinib + evening primrose oil

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• everolimus
Phyrago (dasatinib)

+

everolimus

1 interaction

Monitor/Modify Tx

dasatinib + everolimus

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• exagamglogene autotemcel
Phyrago (dasatinib)

+

exagamglogene autotemcel

1 interaction

Monitor/Modify Tx

dasatinib + exagamglogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• febuxostat
Phyrago (dasatinib)

+

febuxostat

1 interaction

Monitor/Modify Tx

dasatinib + febuxostat

monitor uric acid levels: combo may decr. febuxostat efficacy (antagonistic effects)

• fedratinib
Phyrago (dasatinib)

+

fedratinib

1 interaction

Monitor/Modify Tx

dasatinib + fedratinib

monitor ECG, CBC: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• fenoprofen
Phyrago (dasatinib)

+

fenoprofen

1 interaction

Monitor/Modify Tx

dasatinib + fenoprofen

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• fenugreek
Phyrago (dasatinib)

+

fenugreek

1 interaction

Monitor/Modify Tx

dasatinib + fenugreek

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• filgrastim (G-CSF)
Phyrago (dasatinib)

+

filgrastim (G-CSF)

1 interaction

Monitor/Modify Tx

dasatinib + filgrastim (G-CSF)

admin. filgrastim at least 24h before or after myelosuppressive chemo: combo may decr. filgrastim efficacy (antagonistic effects)

• flecainide
Phyrago (dasatinib)

+

flecainide

1 interaction

Monitor/Modify Tx

dasatinib + flecainide

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fluconazole
Phyrago (dasatinib)

+

fluconazole

1 interaction

Monitor/Modify Tx

dasatinib + fluconazole

monitor ECG, CBC: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• flucytosine
Phyrago (dasatinib)

+

flucytosine

1 interaction

Monitor/Modify Tx

dasatinib + flucytosine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• fluorouracil
Phyrago (dasatinib)

+

fluorouracil

1 interaction

Monitor/Modify Tx

dasatinib + fluorouracil

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fluoxetine
Phyrago (dasatinib)

+

fluoxetine

1 interaction

Monitor/Modify Tx

dasatinib + fluoxetine

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• fluphenazine
Phyrago (dasatinib)

+

fluphenazine

1 interaction

Monitor/Modify Tx

dasatinib + fluphenazine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• flurbiprofen
Phyrago (dasatinib)

+

flurbiprofen

1 interaction

Monitor/Modify Tx

dasatinib + flurbiprofen

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• flurbiprofen ophthalmic
Phyrago (dasatinib)

+

flurbiprofen ophthalmic

1 interaction

Monitor/Modify Tx

dasatinib + flurbiprofen ophthalmic

monitor bleeding s/sx: combo may incr. risk of postop ocular bleeding (additive effects)

• fluvoxamine
Phyrago (dasatinib)

+

fluvoxamine

1 interaction

Monitor/Modify Tx

dasatinib + fluvoxamine

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (hepatic metab. inhibited, additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• fosamprenavir
Phyrago (dasatinib)

+

fosamprenavir

1 interaction

Monitor/Modify Tx

dasatinib + fosamprenavir

monitor ECG, CBC: combo may incr. or decr. dasatinib levels, incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects or decr. efficacy (hepatic metab. altered)

• foscarnet
Phyrago (dasatinib)

+

foscarnet

1 interaction

Monitor/Modify Tx

dasatinib + foscarnet

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• fostamatinib
Phyrago (dasatinib)

+

fostamatinib

1 interaction

Monitor/Modify Tx

dasatinib + fostamatinib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• fruquintinib
Phyrago (dasatinib)

+

fruquintinib

1 interaction

Monitor/Modify Tx

dasatinib + fruquintinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• garlic
Phyrago (dasatinib)

+

garlic

1 interaction

Monitor/Modify Tx

dasatinib + garlic

monitor bleeding s/sx w/ supplemental garlic; dietary intake OK: combo may decr. dasatinib levels, efficacy; may incr. risk of GI or other bleeding, incl. life-threatening (hepatic metab. induced; additive effects)

• gefitinib
Phyrago (dasatinib)

+

gefitinib

1 interaction

Monitor/Modify Tx

dasatinib + gefitinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• gemtuzumab ozogamicin
Phyrago (dasatinib)

+

gemtuzumab ozogamicin

1 interaction

Monitor/Modify Tx

dasatinib + gemtuzumab ozogamicin

monitor platelets, bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• gilteritinib
Phyrago (dasatinib)

+

gilteritinib

1 interaction

Monitor/Modify Tx

dasatinib + gilteritinib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ginkgo
Phyrago (dasatinib)

+

ginkgo

1 interaction

Monitor/Modify Tx

dasatinib + ginkgo

monitor bleeding s/sx: combo may decr. dasatinib levels, efficacy; may incr. risk of GI or other bleeding, incl. life-threatening (hepatic metab. induced; additive effects)

• givinostat
Phyrago (dasatinib)

+

givinostat

1 interaction

Monitor/Modify Tx

dasatinib + givinostat

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• glasdegib
Phyrago (dasatinib)

+

glasdegib

1 interaction

Monitor/Modify Tx

dasatinib + glasdegib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• goserelin
Phyrago (dasatinib)

+

goserelin

1 interaction

Monitor/Modify Tx

dasatinib + goserelin

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• Haemophilus b vaccine
Phyrago (dasatinib)

+

Haemophilus b vaccine

1 interaction

Monitor/Modify Tx

dasatinib + Haemophilus b vaccine

if possible, vaccinate at least 2wk before starting dasatinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• haloperidol
Phyrago (dasatinib)

+

haloperidol

1 interaction

Monitor/Modify Tx

dasatinib + haloperidol

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• heparin
Phyrago (dasatinib)

+

heparin

1 interaction

Monitor/Modify Tx

dasatinib + heparin

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• hepatitis A vaccine
Phyrago (dasatinib)

+

hepatitis A vaccine

1 interaction

Monitor/Modify Tx

dasatinib + hepatitis A vaccine

if possible, vaccinate at least 2wk before starting dasatinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• hepatitis B vaccine
Phyrago (dasatinib)

+

hepatitis B vaccine

1 interaction

Monitor/Modify Tx

dasatinib + hepatitis B vaccine

if possible, vaccinate at least 2wk before starting dasatinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• histrelin
Phyrago (dasatinib)

+

histrelin

1 interaction

Monitor/Modify Tx

dasatinib + histrelin

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• human papillomavirus vaccine
Phyrago (dasatinib)

+

human papillomavirus vaccine

1 interaction

Monitor/Modify Tx

dasatinib + human papillomavirus vaccine

if possible, vaccinate at least 2wk before starting dasatinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• hydrocortisone
Phyrago (dasatinib)

+

hydrocortisone

1 interaction

Monitor/Modify Tx

dasatinib + hydrocortisone

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• hydroxyurea
Phyrago (dasatinib)

+

hydroxyurea

1 interaction

Monitor/Modify Tx

dasatinib + hydroxyurea

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• hydroxyzine
Phyrago (dasatinib)

+

hydroxyzine

1 interaction

Monitor/Modify Tx

dasatinib + hydroxyzine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ibrutinib
Phyrago (dasatinib)

+

ibrutinib

1 interaction

Monitor/Modify Tx

dasatinib + ibrutinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• ibuprofen
Phyrago (dasatinib)

+

ibuprofen

1 interaction

Monitor/Modify Tx

dasatinib + ibuprofen

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• ibuprofen lysine
Phyrago (dasatinib)

+

ibuprofen lysine

1 interaction

Monitor/Modify Tx

dasatinib + ibuprofen lysine

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• ibutilide
Phyrago (dasatinib)

+

ibutilide

1 interaction

Monitor/Modify Tx

dasatinib + ibutilide

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• icosapent ethyl
Phyrago (dasatinib)

+

icosapent ethyl

1 interaction

Monitor/Modify Tx

dasatinib + icosapent ethyl

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• iloprost inhaled
Phyrago (dasatinib)

+

iloprost inhaled

1 interaction

Monitor/Modify Tx

dasatinib + iloprost inhaled

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• imatinib
Phyrago (dasatinib)

+

imatinib

1 interaction

Monitor/Modify Tx

dasatinib + imatinib

monitor ECG, CBC, bleeding s/sx: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, GI or other bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited, additive effects)

• indomethacin
Phyrago (dasatinib)

+

indomethacin

1 interaction

Monitor/Modify Tx

dasatinib + indomethacin

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• influenza H5N1 vaccine
Phyrago (dasatinib)

+

influenza H5N1 vaccine

1 interaction

Monitor/Modify Tx

dasatinib + influenza H5N1 vaccine

if possible, vaccinate at least 2wk before starting dasatinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• influenza vaccine
Phyrago (dasatinib)

+

influenza vaccine

1 interaction

Monitor/Modify Tx

dasatinib + influenza vaccine

if possible, vaccinate at least 2wk before starting dasatinib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• inotuzumab ozogamicin
Phyrago (dasatinib)

+

inotuzumab ozogamicin

1 interaction

Monitor/Modify Tx

dasatinib + inotuzumab ozogamicin

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• interferon beta 1a
Phyrago (dasatinib)

+

interferon beta 1a

1 interaction

Monitor/Modify Tx

dasatinib + interferon beta 1a

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• interferon beta 1b
Phyrago (dasatinib)

+

interferon beta 1b

1 interaction

Monitor/Modify Tx

dasatinib + interferon beta 1b

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• interferon gamma 1b
Phyrago (dasatinib)

+

interferon gamma 1b

1 interaction

Monitor/Modify Tx

dasatinib + interferon gamma 1b

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• isavuconazonium
Phyrago (dasatinib)

+

isavuconazonium

1 interaction

Monitor/Modify Tx

dasatinib + isavuconazonium

monitor ECG, CBC: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• isoflurane
Phyrago (dasatinib)

+

isoflurane

1 interaction

Monitor/Modify Tx

dasatinib + isoflurane

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• Japanese encephalitis vaccine
Phyrago (dasatinib)

+

Japanese encephalitis vaccine

1 interaction

Monitor/Modify Tx

dasatinib + Japanese encephalitis vaccine

if possible, vaccinate at least 2wk before starting dasatinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ketoprofen
Phyrago (dasatinib)

+

ketoprofen

1 interaction

Monitor/Modify Tx

dasatinib + ketoprofen

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• ketorolac
Phyrago (dasatinib)

+

ketorolac

1 interaction

Monitor/Modify Tx

dasatinib + ketorolac

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• ketorolac ophthalmic
Phyrago (dasatinib)

+

ketorolac ophthalmic

1 interaction

Monitor/Modify Tx

dasatinib + ketorolac ophthalmic

monitor bleeding s/sx: combo may incr. risk of postop ocular bleeding (additive effects)

• leflunomide
Phyrago (dasatinib)

+

leflunomide

1 interaction

Monitor/Modify Tx

dasatinib + leflunomide

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• lenacapavir
Phyrago (dasatinib)

+

lenacapavir

1 interaction

Monitor/Modify Tx

dasatinib + lenacapavir

monitor ECG, CBC during and x9mo after lenacapavir tx: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• lenvatinib
Phyrago (dasatinib)

+

lenvatinib

1 interaction

Monitor/Modify Tx

dasatinib + lenvatinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• letermovir
Phyrago (dasatinib)

+

letermovir

1 interaction

Monitor/Modify Tx

dasatinib + letermovir

monitor ECG, CBC: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• leuprolide
Phyrago (dasatinib)

+

leuprolide

1 interaction

Monitor/Modify Tx

dasatinib + leuprolide

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• levofloxacin
Phyrago (dasatinib)

+

levofloxacin

1 interaction

Monitor/Modify Tx

dasatinib + levofloxacin

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• levomilnacipran
Phyrago (dasatinib)

+

levomilnacipran

1 interaction

Monitor/Modify Tx

dasatinib + levomilnacipran

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• lifileucel
Phyrago (dasatinib)

+

lifileucel

1 interaction

Monitor/Modify Tx

dasatinib + lifileucel

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• linezolid
Phyrago (dasatinib)

+

linezolid

1 interaction

Monitor/Modify Tx

dasatinib + linezolid

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• lofexidine
Phyrago (dasatinib)

+

lofexidine

1 interaction

Monitor/Modify Tx

dasatinib + lofexidine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• lovotibeglogene autotemcel
Phyrago (dasatinib)

+

lovotibeglogene autotemcel

1 interaction

Monitor/Modify Tx

dasatinib + lovotibeglogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• lumateperone
Phyrago (dasatinib)

+

lumateperone

1 interaction

Monitor/Modify Tx

dasatinib + lumateperone

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• lymphocyte immune globulin, anti-thymocyte globulin
Phyrago (dasatinib)

+

lymphocyte immune globulin, anti-thymocyte globulin

1 interaction

Monitor/Modify Tx

dasatinib + lymphocyte immune globulin, anti-thymocyte globulin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• macimorelin
Phyrago (dasatinib)

+

macimorelin

1 interaction

Monitor/Modify Tx

dasatinib + macimorelin

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• magnesium carbonate
Phyrago (dasatinib)

+

magnesium carbonate

1 interaction

Monitor/Modify Tx

dasatinib + magnesium carbonate

give dasatinib at least 2h before or 2h after magnesium carbonate: combo may decr. dasatinib levels, efficacy (absorption decreased at higher gastric pH)

• magnesium hydroxide
Phyrago (dasatinib)

+

magnesium hydroxide

1 interaction

Monitor/Modify Tx

dasatinib + magnesium hydroxide

give dasatinib at least 2h before or 2h after magnesium hydroxide: combo may decr. dasatinib levels, efficacy (absorption decreased at higher gastric pH)

• magnesium oxide
Phyrago (dasatinib)

+

magnesium oxide

1 interaction

Monitor/Modify Tx

dasatinib + magnesium oxide

give dasatinib at least 2h before or 2h after magnesium oxide: combo may decr. dasatinib levels, efficacy (absorption decreased at higher gastric pH)

• magnesium salicylate
Phyrago (dasatinib)

+

magnesium salicylate

1 interaction

Monitor/Modify Tx

dasatinib + magnesium salicylate

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• meclofenamate
Phyrago (dasatinib)

+

meclofenamate

1 interaction

Monitor/Modify Tx

dasatinib + meclofenamate

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• mefenamic acid
Phyrago (dasatinib)

+

mefenamic acid

1 interaction

Monitor/Modify Tx

dasatinib + mefenamic acid

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• meloxicam
Phyrago (dasatinib)

+

meloxicam

1 interaction

Monitor/Modify Tx

dasatinib + meloxicam

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• meningococcal vaccine
Phyrago (dasatinib)

+

meningococcal vaccine

1 interaction

Monitor/Modify Tx

dasatinib + meningococcal vaccine

if possible, vaccinate at least 2wk before starting dasatinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• mercaptopurine
Phyrago (dasatinib)

+

mercaptopurine

1 interaction

Monitor/Modify Tx

dasatinib + mercaptopurine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• mesalamine
Phyrago (dasatinib)

+

mesalamine

1 interaction

Monitor/Modify Tx

dasatinib + mesalamine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• mesalamine rectal
Phyrago (dasatinib)

+

mesalamine rectal

1 interaction

Monitor/Modify Tx

dasatinib + mesalamine rectal

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• methadone
Phyrago (dasatinib)

+

methadone

1 interaction

Monitor/Modify Tx

dasatinib + methadone

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• methotrexate
Phyrago (dasatinib)

+

methotrexate

1 interaction

Monitor/Modify Tx

dasatinib + methotrexate

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, GI or other bleeding, incl. life-threatening (additive effects)

• milnacipran
Phyrago (dasatinib)

+

milnacipran

1 interaction

Monitor/Modify Tx

dasatinib + milnacipran

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• monomethyl fumarate
Phyrago (dasatinib)

+

monomethyl fumarate

1 interaction

Monitor/Modify Tx

dasatinib + monomethyl fumarate

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• moxifloxacin
Phyrago (dasatinib)

+

moxifloxacin

1 interaction

Monitor/Modify Tx

dasatinib + moxifloxacin

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• mycophenolate mofetil
Phyrago (dasatinib)

+

mycophenolate mofetil

1 interaction

Monitor/Modify Tx

dasatinib + mycophenolate mofetil

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, GI or other bleeding, incl. life-threatening (additive effects)

• mycophenolic acid
Phyrago (dasatinib)

+

mycophenolic acid

1 interaction

Monitor/Modify Tx

dasatinib + mycophenolic acid

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, GI or other bleeding, incl. life-threatening (additive effects)

• nabumetone
Phyrago (dasatinib)

+

nabumetone

1 interaction

Monitor/Modify Tx

dasatinib + nabumetone

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• naproxen
Phyrago (dasatinib)

+

naproxen

1 interaction

Monitor/Modify Tx

dasatinib + naproxen

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• nattokinase
Phyrago (dasatinib)

+

nattokinase

1 interaction

Monitor/Modify Tx

dasatinib + nattokinase

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• nepafenac ophthalmic
Phyrago (dasatinib)

+

nepafenac ophthalmic

1 interaction

Monitor/Modify Tx

dasatinib + nepafenac ophthalmic

monitor bleeding s/sx: combo may incr. risk of postop ocular bleeding (additive effects)

• netupitant
Phyrago (dasatinib)

+

netupitant

1 interaction

Monitor/Modify Tx

dasatinib + netupitant

monitor ECG, CBC during and x1wk after (fos)netupitant tx: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• niacin (vitamin B3)
Phyrago (dasatinib)

+

niacin (vitamin B3)

1 interaction

Monitor/Modify Tx

dasatinib + niacin (vitamin B3)

monitor platelets, bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• nilotinib
Phyrago (dasatinib)

+

nilotinib

1 interaction

Monitor/Modify Tx

dasatinib + nilotinib

monitor ECG, electrolytes, CBC, bleeding s/sx: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, GI or other bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited, additive effects)

• nintedanib
Phyrago (dasatinib)

+

nintedanib

1 interaction

Monitor/Modify Tx

dasatinib + nintedanib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• nirogacestat
Phyrago (dasatinib)

+

nirogacestat

1 interaction

Monitor/Modify Tx

dasatinib + nirogacestat

monitor ECG, CBC: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• nusinersen
Phyrago (dasatinib)

+

nusinersen

1 interaction

Monitor/Modify Tx

dasatinib + nusinersen

monitor platelets, bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• oliceridine
Phyrago (dasatinib)

+

oliceridine

1 interaction

Monitor/Modify Tx

dasatinib + oliceridine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• olsalazine
Phyrago (dasatinib)

+

olsalazine

1 interaction

Monitor/Modify Tx

dasatinib + olsalazine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• omega-3-acid
Phyrago (dasatinib)

+

omega-3-acid

1 interaction

Monitor/Modify Tx

dasatinib + omega-3-acid

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• ondansetron
Phyrago (dasatinib)

+

ondansetron

1 interaction

Monitor/Modify Tx

dasatinib + ondansetron

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• osimertinib
Phyrago (dasatinib)

+

osimertinib

1 interaction

Monitor/Modify Tx

dasatinib + osimertinib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• oxaliplatin
Phyrago (dasatinib)

+

oxaliplatin

1 interaction

Monitor/Modify Tx

dasatinib + oxaliplatin

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• oxaprozin
Phyrago (dasatinib)

+

oxaprozin

1 interaction

Monitor/Modify Tx

dasatinib + oxaprozin

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• paliperidone
Phyrago (dasatinib)

+

paliperidone

1 interaction

Monitor/Modify Tx

dasatinib + paliperidone

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• palonosetron
Phyrago (dasatinib)

+

palonosetron

1 interaction

Monitor/Modify Tx

dasatinib + palonosetron

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• panobinostat
Phyrago (dasatinib)

+

panobinostat

1 interaction

Monitor/Modify Tx

dasatinib + panobinostat

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• paroxetine
Phyrago (dasatinib)

+

paroxetine

1 interaction

Monitor/Modify Tx

dasatinib + paroxetine

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• pasireotide
Phyrago (dasatinib)

+

pasireotide

1 interaction

Monitor/Modify Tx

dasatinib + pasireotide

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pazopanib
Phyrago (dasatinib)

+

pazopanib

1 interaction

Monitor/Modify Tx

dasatinib + pazopanib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• pegaspargase
Phyrago (dasatinib)

+

pegaspargase

1 interaction

Monitor/Modify Tx

dasatinib + pegaspargase

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• pegfilgrastim (G-CSF)
Phyrago (dasatinib)

+

pegfilgrastim (G-CSF)

1 interaction

Monitor/Modify Tx

dasatinib + pegfilgrastim (G-CSF)

admin. pegfilgrastim >24h after or >14 days before myelosuppressive chemo: combo may decr. pegfilgrastim efficacy (antagonistic effects)

• peginterferon alfa 2a
Phyrago (dasatinib)

+

peginterferon alfa 2a

1 interaction

Monitor/Modify Tx

dasatinib + peginterferon alfa 2a

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• peginterferon beta 1a
Phyrago (dasatinib)

+

peginterferon beta 1a

1 interaction

Monitor/Modify Tx

dasatinib + peginterferon beta 1a

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• pegloticase
Phyrago (dasatinib)

+

pegloticase

1 interaction

Monitor/Modify Tx

dasatinib + pegloticase

monitor uric acid levels: combo may decr. pegloticase efficacy (antagonistic effects)

• penicillin G
Phyrago (dasatinib)

+

penicillin G

1 interaction

Monitor/Modify Tx

dasatinib + penicillin G

monitor bleeding s/sx, especially w/ large penicillin G doses and/or concomitant renal impairment: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• pentamidine
Phyrago (dasatinib)

+

pentamidine

1 interaction

Monitor/Modify Tx

dasatinib + pentamidine

monitor ECG, electrolytes, CBC; risk may be lower w/ nebulized pentamidine: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• pentosan polysulfate sodium
Phyrago (dasatinib)

+

pentosan polysulfate sodium

1 interaction

Monitor/Modify Tx

dasatinib + pentosan polysulfate sodium

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• piperacillin
Phyrago (dasatinib)

+

piperacillin

1 interaction

Monitor/Modify Tx

dasatinib + piperacillin

monitor bleeding s/sx, especially w/ prolonged piperacillin tx and/or concomitant renal impairment: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• piroxicam
Phyrago (dasatinib)

+

piroxicam

1 interaction

Monitor/Modify Tx

dasatinib + piroxicam

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• pirtobrutinib
Phyrago (dasatinib)

+

pirtobrutinib

1 interaction

Monitor/Modify Tx

dasatinib + pirtobrutinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• plasminogen, human
Phyrago (dasatinib)

+

plasminogen, human

1 interaction

Monitor/Modify Tx

dasatinib + plasminogen, human

monitor bleeding s/sx, especially during and x4h after plasminogen infusion: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• pneumococcal vaccine
Phyrago (dasatinib)

+

pneumococcal vaccine

1 interaction

Monitor/Modify Tx

dasatinib + pneumococcal vaccine

if possible, vaccinate at least 2wk before starting dasatinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• poliovirus vaccine
Phyrago (dasatinib)

+

poliovirus vaccine

1 interaction

Monitor/Modify Tx

dasatinib + poliovirus vaccine

if possible, vaccinate at least 2wk before starting dasatinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ponatinib
Phyrago (dasatinib)

+

ponatinib

1 interaction

Monitor/Modify Tx

dasatinib + ponatinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• porfimer
Phyrago (dasatinib)

+

porfimer

1 interaction

Monitor/Modify Tx

dasatinib + porfimer

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• pralsetinib
Phyrago (dasatinib)

+

pralsetinib

1 interaction

Monitor/Modify Tx

dasatinib + pralsetinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• prasugrel
Phyrago (dasatinib)

+

prasugrel

1 interaction

Monitor/Modify Tx

dasatinib + prasugrel

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• probenecid
Phyrago (dasatinib)

+

probenecid

1 interaction

Monitor/Modify Tx

dasatinib + probenecid

monitor uric acid levels: combo may decr. probenecid efficacy (antagonistic effects)

• procainamide
Phyrago (dasatinib)

+

procainamide

1 interaction

Monitor/Modify Tx

dasatinib + procainamide

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• proguanil
Phyrago (dasatinib)

+

proguanil

1 interaction

Monitor/Modify Tx

dasatinib + proguanil

monitor CBC, especially if concomitant renal impairment: combo may incr. risk of myelosuppression (additive effects)

• propafenone
Phyrago (dasatinib)

+

propafenone

1 interaction

Monitor/Modify Tx

dasatinib + propafenone

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pyrimethamine
Phyrago (dasatinib)

+

pyrimethamine

1 interaction

Monitor/Modify Tx

dasatinib + pyrimethamine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• quinidine (antiarrhythmic)
Phyrago (dasatinib)

+

quinidine (antiarrhythmic)

1 interaction

Monitor/Modify Tx

dasatinib + quinidine (antiarrhythmic)

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• quinidine (CYP2D6 inhibitor)
Phyrago (dasatinib)

+

quinidine (CYP2D6 inhibitor)

1 interaction

Monitor/Modify Tx

dasatinib + quinidine (CYP2D6 inhibitor)

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• quinine
Phyrago (dasatinib)

+

quinine

1 interaction

Monitor/Modify Tx

dasatinib + quinine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ramucirumab
Phyrago (dasatinib)

+

ramucirumab

1 interaction

Monitor/Modify Tx

dasatinib + ramucirumab

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• ranibizumab
Phyrago (dasatinib)

+

ranibizumab

1 interaction

Monitor/Modify Tx

dasatinib + ranibizumab

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• rasburicase
Phyrago (dasatinib)

+

rasburicase

1 interaction

Monitor/Modify Tx

dasatinib + rasburicase

monitor uric acid levels: combo may decr. rasburicase efficacy (antagonistic effects)

• regorafenib
Phyrago (dasatinib)

+

regorafenib

1 interaction

Monitor/Modify Tx

dasatinib + regorafenib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• respiratory syncytial virus vaccine
Phyrago (dasatinib)

+

respiratory syncytial virus vaccine

1 interaction

Monitor/Modify Tx

dasatinib + respiratory syncytial virus vaccine

if possible, vaccinate at least 2wk before starting dasatinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• resveratrol
Phyrago (dasatinib)

+

resveratrol

1 interaction

Monitor/Modify Tx

dasatinib + resveratrol

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• reteplase
Phyrago (dasatinib)

+

reteplase

1 interaction

Monitor/Modify Tx

dasatinib + reteplase

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• revakinagene taroretcel
Phyrago (dasatinib)

+

revakinagene taroretcel

1 interaction

Monitor/Modify Tx

dasatinib + revakinagene taroretcel

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• revumenib
Phyrago (dasatinib)

+

revumenib

1 interaction

Monitor/Modify Tx

dasatinib + revumenib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ribavirin
Phyrago (dasatinib)

+

ribavirin

1 interaction

Monitor/Modify Tx

dasatinib + ribavirin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• rituximab
Phyrago (dasatinib)

+

rituximab

1 interaction

Monitor/Modify Tx

dasatinib + rituximab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• rivaroxaban
Phyrago (dasatinib)

+

rivaroxaban

1 interaction

Monitor/Modify Tx

dasatinib + rivaroxaban

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• romidepsin
Phyrago (dasatinib)

+

romidepsin

1 interaction

Monitor/Modify Tx

dasatinib + romidepsin

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• rucaparib
Phyrago (dasatinib)

+

rucaparib

1 interaction

Monitor/Modify Tx

dasatinib + rucaparib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ruxolitinib topical
Phyrago (dasatinib)

+

ruxolitinib topical

1 interaction

Monitor/Modify Tx

dasatinib + ruxolitinib topical

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• salsalate
Phyrago (dasatinib)

+

salsalate

1 interaction

Monitor/Modify Tx

dasatinib + salsalate

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• sargramostim (GM-CSF)
Phyrago (dasatinib)

+

sargramostim (GM-CSF)

1 interaction

Monitor/Modify Tx

dasatinib + sargramostim (GM-CSF)

admin. sargramostim >24h before or after myelosuppressive chemo: combo may decr. sargramostim efficacy (antagonistic effects)

• sarilumab
Phyrago (dasatinib)

+

sarilumab

1 interaction

Monitor/Modify Tx

dasatinib + sarilumab

monitor CBC: combo may decr. dasatinib levels, efficacy; may incr. risk of myelosuppression (hepatic metab. altered; sarilumab may reverse inflammatory cytokine-induced downregulation of CYP450 enzymes resulting in relative induction of enzymes upon tx start and downregulation upon D/C; additive effects)

• satralizumab
Phyrago (dasatinib)

+

satralizumab

1 interaction

Monitor/Modify Tx

dasatinib + satralizumab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• saw palmetto
Phyrago (dasatinib)

+

saw palmetto

1 interaction

Monitor/Modify Tx

dasatinib + saw palmetto

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• selpercatinib
Phyrago (dasatinib)

+

selpercatinib

1 interaction

Monitor/Modify Tx

dasatinib + selpercatinib

monitor ECG, electrolytes, bleeding s/sx: combo may incr. risk of QT prolongation, cardiac arrhythmias, GI or other bleeding, incl. life-threatening (additive effects)

• selumetinib
Phyrago (dasatinib)

+

selumetinib

1 interaction

Monitor/Modify Tx

dasatinib + selumetinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects, antiplatelet and anticoagulant effects augmented by vitamin E content in selumetinib capsules)

• sepiapterin
Phyrago (dasatinib)

+

sepiapterin

1 interaction

Monitor/Modify Tx

dasatinib + sepiapterin

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• sertraline
Phyrago (dasatinib)

+

sertraline

1 interaction

Monitor/Modify Tx

dasatinib + sertraline

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• sevoflurane
Phyrago (dasatinib)

+

sevoflurane

1 interaction

Monitor/Modify Tx

dasatinib + sevoflurane

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sirolimus
Phyrago (dasatinib)

+

sirolimus

1 interaction

Monitor/Modify Tx

dasatinib + sirolimus

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• sirolimus albumin-bound
Phyrago (dasatinib)

+

sirolimus albumin-bound

1 interaction

Monitor/Modify Tx

dasatinib + sirolimus albumin-bound

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• smallpox/mpox vaccine, live
Phyrago (dasatinib)

+

smallpox/ mpox vaccine, live

1 interaction

Monitor/Modify Tx

dasatinib + smallpox/ mpox vaccine, live

consider vaccinating at least 4wk before or 3mo after dasatinib tx: combo may result in inadequate vaccine response (immunosuppressive effects)

• sodium bicarbonate
Phyrago (dasatinib)

+

sodium bicarbonate

1 interaction

Monitor/Modify Tx

dasatinib + sodium bicarbonate

give dasatinib at least 2h before or 2h after oral sodium bicarbonate: combo may decr. dasatinib levels, efficacy (absorption decreased at higher gastric pH)

• sodium citrate
Phyrago (dasatinib)

+

sodium citrate

1 interaction

Monitor/Modify Tx

dasatinib + sodium citrate

give dasatinib at least 2h before or 2h after sodium citrate: combo may decr. dasatinib levels, efficacy (absorption decreased at higher gastric pH)

• sodium zirconium cyclosilicate
Phyrago (dasatinib)

+

sodium zirconium cyclosilicate

1 interaction

Monitor/Modify Tx

dasatinib + sodium zirconium cyclosilicate

give dasatinib at least 2h before or 2h after sodium zirconium cyclosilicate: combo may decr. dasatinib levels, efficacy (absorption decreased at higher gastric pH)

• sorafenib
Phyrago (dasatinib)

+

sorafenib

1 interaction

Monitor/Modify Tx

dasatinib + sorafenib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• sotatercept
Phyrago (dasatinib)

+

sotatercept

1 interaction

Monitor/Modify Tx

dasatinib + sotatercept

monitor platelets, bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• stiripentol
Phyrago (dasatinib)

+

stiripentol

1 interaction

Monitor/Modify Tx

dasatinib + stiripentol

monitor CBC: combo may decr. dasatinib levels, efficacy; may incr. risk of myelosuppression (hepatic metab. possibly induced; additive effects)

• succimer
Phyrago (dasatinib)

+

succimer

1 interaction

Monitor/Modify Tx

dasatinib + succimer

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• sulfasalazine
Phyrago (dasatinib)

+

sulfasalazine

1 interaction

Monitor/Modify Tx

dasatinib + sulfasalazine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• sulindac
Phyrago (dasatinib)

+

sulindac

1 interaction

Monitor/Modify Tx

dasatinib + sulindac

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• sunitinib
Phyrago (dasatinib)

+

sunitinib

1 interaction

Monitor/Modify Tx

dasatinib + sunitinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• telavancin
Phyrago (dasatinib)

+

telavancin

1 interaction

Monitor/Modify Tx

dasatinib + telavancin

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• tenecteplase
Phyrago (dasatinib)

+

tenecteplase

1 interaction

Monitor/Modify Tx

dasatinib + tenecteplase

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• teplizumab
Phyrago (dasatinib)

+

teplizumab

1 interaction

Monitor/Modify Tx

dasatinib + teplizumab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• teriflunomide
Phyrago (dasatinib)

+

teriflunomide

1 interaction

Monitor/Modify Tx

dasatinib + teriflunomide

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• tetrabenazine
Phyrago (dasatinib)

+

tetrabenazine

1 interaction

Monitor/Modify Tx

dasatinib + tetrabenazine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• thalidomide
Phyrago (dasatinib)

+

thalidomide

1 interaction

Monitor/Modify Tx

dasatinib + thalidomide

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ticagrelor
Phyrago (dasatinib)

+

ticagrelor

1 interaction

Monitor/Modify Tx

dasatinib + ticagrelor

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• tick-borne encephalitis vaccine
Phyrago (dasatinib)

+

tick-borne encephalitis vaccine

1 interaction

Monitor/Modify Tx

dasatinib + tick-borne encephalitis vaccine

if possible, vaccinate at least 2wk before starting dasatinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tirofiban
Phyrago (dasatinib)

+

tirofiban

1 interaction

Monitor/Modify Tx

dasatinib + tirofiban

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• tisotumab vedotin
Phyrago (dasatinib)

+

tisotumab vedotin

1 interaction

Monitor/Modify Tx

dasatinib + tisotumab vedotin

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• tivozanib
Phyrago (dasatinib)

+

tivozanib

1 interaction

Monitor/Modify Tx

dasatinib + tivozanib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• tocilizumab
Phyrago (dasatinib)

+

tocilizumab

1 interaction

Monitor/Modify Tx

dasatinib + tocilizumab

monitor CBC: combo may decr. dasatinib levels, efficacy; may incr. risk of myelosuppression (hepatic metab. altered; tocilizumab may reverse inflammatory cytokine-induced downregulation of CYP450 enzymes resulting in relative induction of enzymes; additive effects)

• tofacitinib
Phyrago (dasatinib)

+

tofacitinib

1 interaction

Monitor/Modify Tx

dasatinib + tofacitinib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• tolmetin
Phyrago (dasatinib)

+

tolmetin

1 interaction

Monitor/Modify Tx

dasatinib + tolmetin

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• tovorafenib
Phyrago (dasatinib)

+

tovorafenib

1 interaction

Monitor/Modify Tx

dasatinib + tovorafenib

monitor bleeding s/sx: combo may decr. dasatinib levels, efficacy; may incr. risk of GI or other bleeding, incl. life-threatening (hepatic metab. induced; additive effects)

• tramadol
Phyrago (dasatinib)

+

tramadol

1 interaction

Monitor/Modify Tx

dasatinib + tramadol

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• trametinib
Phyrago (dasatinib)

+

trametinib

1 interaction

Monitor/Modify Tx

dasatinib + trametinib

monitor bleeding s/sx, especially w/ concomitant dabrafenib use: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• trazodone
Phyrago (dasatinib)

+

trazodone

1 interaction

Monitor/Modify Tx

dasatinib + trazodone

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• treprostinil
Phyrago (dasatinib)

+

treprostinil

1 interaction

Monitor/Modify Tx

dasatinib + treprostinil

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• triclabendazole
Phyrago (dasatinib)

+

triclabendazole

1 interaction

Monitor/Modify Tx

dasatinib + triclabendazole

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• trifluridine
Phyrago (dasatinib)

+

trifluridine

1 interaction

Monitor/Modify Tx

dasatinib + trifluridine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• trimethoprim
Phyrago (dasatinib)

+

trimethoprim

1 interaction

Monitor/Modify Tx

dasatinib + trimethoprim

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• triptorelin
Phyrago (dasatinib)

+

triptorelin

1 interaction

Monitor/Modify Tx

dasatinib + triptorelin

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• typhoid vaccine
Phyrago (dasatinib)

+

typhoid vaccine

1 interaction

Monitor/Modify Tx

dasatinib + typhoid vaccine

if possible, vaccinate at least 2wk before starting dasatinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• upadacitinib
Phyrago (dasatinib)

+

upadacitinib

1 interaction

Monitor/Modify Tx

dasatinib + upadacitinib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, GI or other bleeding, incl. life-threatening (additive effects)

• vadadustat
Phyrago (dasatinib)

+

vadadustat

1 interaction

Monitor/Modify Tx

dasatinib + vadadustat

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• valproic acid
Phyrago (dasatinib)

+

valproic acid

1 interaction

Monitor/Modify Tx

dasatinib + valproic acid

monitor bleeding s/sx, CBC: combo may incr. risk of GI or other bleeding (incl. life-threatening), myelosuppression (additive effects)

• vancomycin
Phyrago (dasatinib)

+

vancomycin

1 interaction

Monitor/Modify Tx

dasatinib + vancomycin

VANCOMYCIN IV: monitor CBC, especially w/ long-term vancomycin; VANCOMYCIN PO use OK: combo may incr. risk of myelosuppression (additive effects)

• vemurafenib
Phyrago (dasatinib)

+

vemurafenib

1 interaction

Monitor/Modify Tx

dasatinib + vemurafenib

monitor ECG, electrolytes: combo may decr. dasatinib levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metab. induced; additive effects)

• venlafaxine
Phyrago (dasatinib)

+

venlafaxine

1 interaction

Monitor/Modify Tx

dasatinib + venlafaxine

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• verapamil
Phyrago (dasatinib)

+

verapamil

1 interaction

Monitor/Modify Tx

dasatinib + verapamil

monitor ECG, CBC: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• vilazodone
Phyrago (dasatinib)

+

vilazodone

1 interaction

Monitor/Modify Tx

dasatinib + vilazodone

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• vinpocetine
Phyrago (dasatinib)

+

vinpocetine

1 interaction

Monitor/Modify Tx

dasatinib + vinpocetine

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• vorapaxar
Phyrago (dasatinib)

+

vorapaxar

1 interaction

Monitor/Modify Tx

dasatinib + vorapaxar

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• vortioxetine
Phyrago (dasatinib)

+

vortioxetine

1 interaction

Monitor/Modify Tx

dasatinib + vortioxetine

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• warfarin
Phyrago (dasatinib)

+

warfarin

1 interaction

Monitor/Modify Tx

dasatinib + warfarin

monitor INR, bleeding s/sx: combo may incr. risk of bleeding, incl. life-threatening (synergistic effects)

• willow bark
Phyrago (dasatinib)

+

willow bark

1 interaction

Monitor/Modify Tx

dasatinib + willow bark

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects, willow bark may contain salicylates)

• zanubrutinib
Phyrago (dasatinib)

+

zanubrutinib

1 interaction

Monitor/Modify Tx

dasatinib + zanubrutinib

monitor bleeding s/sx: combo may decr. dasatinib levels, efficacy; may incr. risk of GI or other bleeding, incl. life-threatening (hepatic metab. induced; additive effects)

• zidovudine
Phyrago (dasatinib)

+

zidovudine

1 interaction

Monitor/Modify Tx

dasatinib + zidovudine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ziv-aflibercept
Phyrago (dasatinib)

+

ziv-aflibercept

1 interaction

Monitor/Modify Tx

dasatinib + ziv-aflibercept

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)